¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2021³â ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2021-02-27

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2021³â ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2021-02-27
±³À°ÀÏÀÚ : 2021-02-27
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ 
±³À°ÁÖÁ¦ : 2021³â ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥      
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ  
´ã´çÀÚ : °¡¿Â
¿¬¶ôó : 02-2038-7988  
À̸ÞÀÏ : gaonpco@gaonpco.com      
±³À°Á¾·ù : ºñ´¢ÀÇÇаú      
Âü¼®¿¹»óÀοø : 30¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í 1. »çÀüµî·Ï ȸ¿ø:¹«·áµî·Ï / ºñȸ¿ø:100,000¿ø / Àü°øÀÇ ¹× °£È£»ç: ¹«·áµî·Ï 2. ÇöÀåµî·Ï: ºÒ°¡      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ13:00~13:20 PC in Patients with CP or CPPS  ¾çÈñÁ¶(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ13:20~13:40 PC in Patients with BPH or Prostate Cancer  ¹ÚÁعé(±¹¸³°æÂûº´¿ø) 
Åä·Ð 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ13:40~14:00 Åä·Ð  Á¶¿ø¿­(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ14:00~14:20 ºñ´¢»ý½Ä±â °¨¿°ÀÇ ºÐÀÚÀ¯ÀüÇР À̹̰æ(Áß¾ÓÀÇ´ë) 
È޽Ġ02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ14:20~14:35 Coffee Break  () 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ14:35~14:50 Guideline for the Management of Asymptomatic Bacteriuria  ½ÅÁÖÇö(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ14:50~15:05 The Role of Immunotherapy in Asymptomatic Bacteriuria  ÀÌÁ¤¿ì(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ15:05~15:20 The Role of Probiotics in Asymptomatic Bacteriuria  Á¶¼®(ÀÎÁ¦ÀÇ´ë) 
Åä·Ð 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ15:20~15:40 Åä·Ð  () 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ15:40~15:55 Urological Management of HIV-Positive Patients  ÀÌÁÖ¿ë(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ15:55~16:10 COVID-19: Urological Manifestations, Viral RNA Detection and Special Considerations in Urological Conditions  ÃÖÁß¿ø(Áß¾Óº¸Èƺ´¿ø) 
Åä·Ð 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ16:10~16:25 Åä·Ð  ¹ÚÈïÀç(¼º±Õ°üÀÇ´ë) 
È޽Ġ02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ16:25~16:40 Coffee Break  () 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ16:40~16:55 Antimicrobial Resistance of Neisseria Gonorrhoeae, Current State  Á¶ÀÎâ(±¹¸³°æÂûº´¿ø) 
±³À°½Ã°£ 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ16:55~17:10 Recent Updates of Male HPV Vaccination  ¹è»ó¶ô(°¡Å縯ÀÇ´ë) 
Åä·Ð 02¿ù 27ÀÏ ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ17:10~17:30 Åä·Ð  Á¶¿µ»ï(¼º±Õ°üÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2021³â ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2021-02-27""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) Á¦32ȸ ¼­¶ó¹ú ¼Ò¾Æû¼Ò³â°ú Çмú´ëȸ : 2021-02-28
´ÙÀ½±Û ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ (¿Â¶óÀÎ) 2021 School of Endocrine Surgeons : 2021-02-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
497 ¼­¿ï °æÈñ´ëÇб³º´¿ø 2018 KYUNG HEE SHOULDER SYMPOSIUM : 2018-09-08 0 1,517 2018-08-22
496 ´ë±¸ °æºÏ´ëÇб³º´¿ø Á¦ 3Â÷ °³¿øÀǸ¦ À§ÇÑ ´ëÇѺÎÁ¤¸ÆÇÐȸ ¿¬¼ö±³À° : 2018-09-07 0 749 2018-08-22
495 °­¿ø ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø NAFLD(non-alcoholic fatty liver disease) and Cardiometabolic Syndrome [7th Gangwon Heart Seminar 2018] : 2018-09-07 0 922 2018-08-22
494 ÀüºÏ ÀüÁÖ ¿¹¼öº´¿ø ´ëÇÑÀçÈ°ÀÇÇÐȸ È£³²Á¦ÁÖÁöȸ ÀçÈ° ½ÉÆ÷Áö¾ö : 2018-09-07 0 1,040 2018-08-22
493 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-07 0 850 2018-08-22
492 ¼­¿ï 2018³â °³¿øÀǸ¦ À§ÇÑ °­µ¿°æÈñ´ëÇб³º´¿ø ¼ÒÈ­±âÁúȯ ¿¬¼ö°­Á : 2018-09-06 0 683 2018-08-22
491 Ãæ³² ´Ü±¹´ëÇб³º´¿ø 2018³â Á¦3Â÷ ´ëÇѺ´¸®ÇÐȸ ´ëÀü¤ýÃæûÁöȸ: ÃÖ½ÅÀÇÇÐÁ¤º¸ Ư°­ ¹× º´¸®ÇÐ Áõ·Ê ¹ßÇ¥ : 2018-09-06 0 769 2018-08-22
490 ´ë±¸ ´ëÇѽŻý¾ÆÇÐȸ ´ë±¸°æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 992 2018-08-22
489 Àü³² Á¦257Â÷ ´ëÇѳ»°úÇÐȸ ±¤ÁÖÀü³²Áöȸ Çмú´ëȸ : 2018-09-06 0 574 2018-08-22
488 °æ³² ´ëÇÑÇǺΰúÇÐȸ º£Ã¼Æ®º´ÀÇ ÃÖ½ÅÁö°ß¿¡ °üÇÏ¿© : 2018-09-06 0 717 2018-08-22
487 Ãæ³² °Ç¾ç´ëÇб³º´¿ø ´ëÇÑÇǺΰúÇÐȸ ÃæûÁöºÎÇÐȸ : 2018-09-06 0 897 2018-08-22
486 ´ë±¸ °è¸í´ëÇб³ µ¿»êÀÇ·á¿ø ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ Á¦234Â÷ °æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 741 2018-08-22
485 °æ±â °¡Å縯´ëÇб³ ºÎõ¼º¸ðº´¿ø ´ëÇѺñ´¢±â°úÇÐȸ 2018 Á¦ 3Â÷ ÀÎõ.°æ±âÁöȸ Áý´ãȸ : 2018-09-06 2 1,474 2018-08-22
484 °æ³² ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018³âµµ 3Â÷ ºÎ»ê¿ï»ê°æ³² ÈäºÎ¿Ü°ú Áý´ãȸ ¹× °­¿¬ : 2018-09-06 0 695 2018-08-22
483 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú 2Çбâ Áö¿ªÀÇ»çÁý´ãȸ : 2018-09-06 0 532 2018-08-22
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷